According to an investigation published on November, 9 by the Journal of the National Cancer Institute, researchers have discovered that the health benefits of fecal immunochemical testing (FIT) is more effective than guaiac fecal occult blood testing (gFOBT) at equal or lower costs at all levels of colonoscopy capacity. Individuals can wait up to 12 weeks for colonoscopy screening in many countries and despite evidence that gFOBT reduces mortality rates from colorectal cancer (CRC), the effectiveness of the screening nevertheless partially depends on patients attending all screening rounds and on the ratio of patients found with CRC or adenomas (diagnostic yield). FIT is of increasing interest in the field as it may increase patient attendance and diagnostic yield in comparison to gFOBT, and also causing less false positive tests.
Cardica, Inc. (Nasdaq: CRDC) announced that the first patients have been enrolled and discharged from the first two investigative sites in a European clinical study to evaluate its MicroCutter™ surgical cutting/stapling devices for transections, resections and anastomoses during gastrointestinal surgical procedures. The planned MicroCutter product line is designed to provide true multi-fire and reloadable cartridge capabilities, with all MicroCutter devices designed to offer both stapling and cutting functionality. With low force-to-fire and small shaft diameters of eight millimeters for the MicroCutter™ XPRESS™ 30 device and five millimeters for the planned MicroCutter™ XCHANGE™ 30 device, the MicroCutter surgical stapling devices should provide flexibility and wide field access during laparoscopic surgical procedures.
PA32540 Plus Clopidogrel Dosed Separately Tops Standard Dual Antiplatelet Therapy With Delayed-Release Omeprazole For Platelet Inhibition
ORLANDO - Dual antiplatelet therapy (DAPT) with PA32540 and clopidogrel spaced 10 hours apart provides better platelet inhibition than concurrent administration of enteric-coated omeprazole (40 mg), enteric-coated aspirin (81 mg), and clopidogrel (300 mg loading/75 mg daily), according to results of the phase I Co-Rx study released at the American Heart Association (AHA) Scientific Sessions 2011. PA32540 is an investigational coordinated-delivery tablet of immediate-release omeprazole (40 mg), a proton pump inhibitor, layered around enteric-coated aspirin (325 mg). The product was developed to provide the cardiovascular benefits of aspirin but with a lower incidence of gastric ulcers than enteric-coated aspirin alone. Principal investigator Paul Gurbel, MD, Director of Cardiovascular Research at the Center for Thrombosis Research at Sinai Hospital of Baltimore, said: "These results provide important insight into the interaction between omeprazole and clopidogrel.
Black senior citizens who need surgery for the intestinal disorder diverticulitis are significantly more likely to die in the hospital than their equally ill white counterparts, even when each racial group carries the same health insurance, new Johns Hopkins research suggests. While all of the patients in the study required surgery, black patients were 26 percent more likely than white patients to undergo riskier and more expensive emergency diverticulitis surgery rather than "elective" scheduled surgery for their condition, the Hopkins researchers found. The results emerged in a study of data from Medicare, the government health insurance for senior citizens. Black seniors also spent more time in the hospital recovering from their operations and the costs of their stays averaged nearly $30, 000 more than those of comparable white patients.
Scientists at Washington University School of Medicine in St. Louis have shown that taking a probiotic before radiation therapy can protect the intestine from damage - at least in mice. The new study suggests that taking a probiotic also may help cancer patients avoid intestinal injury, a common problem in those receiving radiation therapy for abdominal cancers. The research is published online in the journal Gut. Radiation therapy often is used to treat prostate, cervical, bladder, endometrial and other abdominal cancers. But the therapy can kill both cancer cells and healthy ones, leading to severe bouts of diarrhea if the lining of the intestine gets damaged. "For many patients, this means radiation therapy must be discontinued, or the radiation dose reduced, while the intestine heals, " says senior investigator William F.